PL2076260T3 - Związki N-metyloaminometylo-izoindolu, kompozycje zawierające te związki, oraz metody ich stosowania - Google Patents

Związki N-metyloaminometylo-izoindolu, kompozycje zawierające te związki, oraz metody ich stosowania

Info

Publication number: PL2076260T3
Authority: PL; Poland
Prior art keywords: compositions; methods; same; isoindole compounds; methylaminomethyl
Prior art date: 2006-09-15

Application number

PL07838415T

Other languages

English (en)

Inventor

George W Muller

Roger S C Chen

Original Assignee

Celgene Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-15

Filing date

2007-09-14

Publication date

2011-08-31

2007-09-14 Application filed by Celgene Corp filed Critical Celgene Corp

2011-08-31 Publication of PL2076260T3 publication Critical patent/PL2076260T3/pl

Links

GMFNCQYHNCIWFM-UHFFFAOYSA-N 1-isoindol-2-yl-N-methylmethanamine Chemical class C1=CC=CC2=CN(CNC)C=C21 GMFNCQYHNCIWFM-UHFFFAOYSA-N 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Immunology (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Anesthesiology (AREA)
Ophthalmology & Optometry (AREA)
Tropical Medicine & Parasitology (AREA)
Pregnancy & Childbirth (AREA)
Diabetes (AREA)
Hematology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Indole Compounds (AREA)

PL07838415T 2006-09-15 2007-09-14 Związki N-metyloaminometylo-izoindolu, kompozycje zawierające te związki, oraz metody ich stosowania PL2076260T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US84522706P	2006-09-15	2006-09-15
EP07838415A EP2076260B1 (en)	2006-09-15	2007-09-14	N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
PCT/US2007/020201 WO2008033567A1 (en)	2006-09-15	2007-09-14	N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same

Publications (1)

Publication Number	Publication Date
PL2076260T3 true PL2076260T3 (pl)	2011-08-31

Family

ID=38983295

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL07838415T PL2076260T3 (pl)	2006-09-15	2007-09-14	Związki N-metyloaminometylo-izoindolu, kompozycje zawierające te związki, oraz metody ich stosowania

Country Status (30)

Country	Link
US (2)	US8648096B2 (pl)
EP (1)	EP2076260B1 (pl)
JP (1)	JP5567339B2 (pl)
KR (1)	KR20090050107A (pl)
CN (2)	CN103382197A (pl)
AR (1)	AR062875A1 (pl)
AT (1)	ATE502634T1 (pl)
CA (1)	CA2663376C (pl)
CL (1)	CL2007002670A1 (pl)
CO (1)	CO6180446A2 (pl)
CR (1)	CR10696A (pl)
CY (1)	CY1112558T1 (pl)
DE (1)	DE602007013436D1 (pl)
DK (1)	DK2076260T3 (pl)
ES (1)	ES2361584T3 (pl)
HR (1)	HRP20110261T1 (pl)
IL (1)	IL197566A0 (pl)
MX (1)	MX2009002666A (pl)
NI (1)	NI200900031A (pl)
NZ (1)	NZ575689A (pl)
PE (1)	PE20080832A1 (pl)
PL (1)	PL2076260T3 (pl)
PT (1)	PT2076260E (pl)
RS (1)	RS51725B (pl)
RU (1)	RU2009114159A (pl)
SI (1)	SI2076260T1 (pl)
TW (1)	TW200819435A (pl)
UA (1)	UA95975C2 (pl)
WO (1)	WO2008033567A1 (pl)
ZA (1)	ZA200901852B (pl)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2007002521A (es) *	2004-09-03	2007-05-09	Celgene Corp	Procesos para la preparacion de 2-(2,6-dioxopiperidin-3-il)-1- oxoisoindolinas sustituidas.
KR101299321B1 (ko)	2005-06-30	2013-08-26	셀진 코포레이션	4-아미노-2-(2,6-디옥소피페리딘-3-일)이소인돌린-1,3-디온화합물의 제조 방법
DK2076260T3 (da) *	2006-09-15	2011-06-27	Celgene Corp	N-methylaminomethyl-isoindol-forbindelser og sammensætninger, der indeholder disse, samt fremgangsmåder til deres anvendelse
US20100160368A1 (en)	2008-08-18	2010-06-24	Gregory Jefferson J	Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
ES2662407T3 (es)	2008-10-29	2018-04-06	Celgene Corporation	Compuestos isoindolina para uso en el tratamiento del cáncer
SMT201900195T1 (it)	2008-12-19	2019-05-10	Medicis Pharmaceutical Corp	Formulazioni di imiquimod a forza di dosaggio inferiore e regimi di dosaggi brevi per il trattamento di cheratosi attinica
ES2653313T3 (es)	2009-07-13	2018-02-06	Medicis Pharmaceutical Corporation	Formulaciones de imiquimod con concentración de dosificación menor y regímenes de dosificación cortos para el tratamiento de verrugas genitales y perianales
HUE042011T2 (hu)	2010-02-11	2019-06-28	Celgene Corp	Arilmetoxi-izoindolin-származékok, azok készítményei és alkalmazási módszereik
US9090585B2 (en)	2011-03-28	2015-07-28	Deuterx, Llc	2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds
US11295846B2 (en)	2011-12-21	2022-04-05	Deka Products Limited Partnership	System, method, and apparatus for infusing fluid
EP2943201B2 (en)	2013-01-14	2020-07-29	Deuterx, LLC	3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
SG11201506972PA (en)	2013-03-14	2015-10-29	Epizyme Inc	Arginine methyltransferase inhibitors and uses thereof
US9394258B2 (en)	2013-03-14	2016-07-19	Epizyme, Inc.	Arginine methyltransferase inhibitors and uses thereof
EP2970133B1 (en)	2013-03-14	2018-10-24	Epizyme, Inc.	Pyrazole derivatives as prmt1 inhibitors and uses thereof
EP2970131B1 (en)	2013-03-14	2017-11-15	Epizyme, Inc.	Arginine methyltransferase inhibitors and uses thereof
JP2016518336A (ja)	2013-03-14	2016-06-23	エピザイム，インコーポレイティド	Ｐｒｍｔ１阻害剤としてのピラゾール誘導体およびその使用
US9290475B2 (en)	2013-03-14	2016-03-22	Deuterx, Llc	3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
US9120757B2 (en)	2013-03-14	2015-09-01	Epizyme, Inc.	Arginine methyltransferase inhibitors and uses thereof
WO2014144659A1 (en)	2013-03-14	2014-09-18	Epizyme, Inc.	Pyrazole derivatives as prmt1 inhibitors and uses thereof
CA2903264A1 (en)	2013-03-14	2014-11-06	Epizyme, Inc.	Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
US9045455B2 (en)	2013-03-14	2015-06-02	Epizyme, Inc.	Arginine methyltransferase inhibitors and uses thereof
US9133189B2 (en)	2013-03-14	2015-09-15	Epizyme, Inc.	Arginine methyltransferase inhibitors and uses thereof
CA2908954C (en)	2013-04-17	2021-08-03	Signal Pharmaceuticals, Llc	Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer
UA117141C2 (uk)	2013-10-08	2018-06-25	Селджин Корпорейшн	Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
BR112017002403A2 (pt)	2014-08-07	2017-12-05	Calithera Biosciences Inc	formas de cristais de inibidores de glutaminase
CN105566290B (zh) *	2014-10-30	2020-05-22	康朴生物医药技术（上海）有限公司	异吲哚啉衍生物、其中间体、制备方法、药物组合物及应用
US9809603B1 (en)	2015-08-18	2017-11-07	Deuterx, Llc	Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
US10449168B2 (en)	2015-08-31	2019-10-22	The University Of Toledo	Potent phthalate inhibitors of aspartate N-acetyltransferase and selective aspartate pathway inhibitors
JP6448867B2 (ja)	2015-12-15	2019-01-09	アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａＡｋｔｉｅｂｏｌａｇ	イソインドール化合物
AU2017246453A1 (en) *	2016-04-06	2018-11-08	The Regents Of The University Of Michigan	Monofunctional intermediates for ligand-dependent target protein degradation
EP3454856B1 (en)	2016-05-10	2024-09-11	C4 Therapeutics, Inc.	Heterocyclic degronimers for target protein degradation
CN120887906A (zh)	2016-05-10	2025-11-04	C4医药公司	用于靶蛋白降解的螺环降解决定子体
CN109641874A (zh)	2016-05-10	2019-04-16	C4医药公司	用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN109790143A (zh)	2016-05-10	2019-05-21	C4医药公司	用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CA3041840A1 (en)	2016-10-28	2018-05-03	Icahn School Of Medicine At Mount Sinai	Compositions and methods for treating ezh2-mediated cancer
US11541051B2 (en)	2016-12-08	2023-01-03	Icahn School Of Medicine At Mount Sinai	Compositions and methods for treating CDK4/6-mediated cancer
WO2018229155A1 (en)	2017-06-14	2018-12-20	Astrazeneca Ab	2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
WO2018237026A1 (en)	2017-06-20	2018-12-27	C4 Therapeutics, Inc.	N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS
WO2019043208A1 (en)	2017-09-04	2019-03-07	F. Hoffmann-La Roche Ag	DIHYDROQUINOLINONES
WO2019043217A1 (en)	2017-09-04	2019-03-07	F. Hoffmann-La Roche Ag	DIHYDROBENZIMIDAZOLONES
EP3679026A1 (en)	2017-09-04	2020-07-15	C4 Therapeutics, Inc.	Glutarimide
EP3710002A4 (en)	2017-11-16	2021-07-07	C4 Therapeutics, Inc.	DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
CA3092677A1 (en)	2018-03-06	2019-09-12	Icahn School Of Medicine At Mount Sinai	Serine threonine kinase (akt) degradation / disruption compounds and methods of use
CN111902141A (zh)	2018-03-26	2020-11-06	C4医药公司	用于ikaros降解的羟脑苷脂结合剂
CN119751456A (zh)	2018-04-16	2025-04-04	C4医药公司	螺环化合物
AU2019261273B2 (en) *	2018-04-23	2023-03-09	Celgene Corporation	Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma
EP3578561A1 (en)	2018-06-04	2019-12-11	F. Hoffmann-La Roche AG	Spiro compounds
EP3810145A4 (en)	2018-06-21	2022-06-01	Icahn School of Medicine at Mount Sinai	Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
ES2963694T3 (es)	2018-07-10	2024-04-01	Novartis Ag	Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y su uso en el tratamiento de enfermedades dependientes de la proteína con dedos de cinc 2 de la familia ikaros (ikzf2)
WO2020132561A1 (en)	2018-12-20	2020-06-25	C4 Therapeutics, Inc.	Targeted protein degradation
CN113557235B (zh)	2019-03-06	2025-08-08	C4医药公司	用于药物治疗的杂环化合物
AR119715A1 (es) *	2019-04-12	2022-01-05	Celgene Corp	Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona
MA55628A (fr)	2019-04-12	2022-02-16	C4 Therapeutics Inc	Agents de dégradation tricycliques d'ikaros et d'aiolos
CN118908962A (zh)	2019-05-06	2024-11-08	西奈山伊坎医学院	作为hpk1的降解剂的异双功能化合物
CA3154890A1 (en) *	2019-10-21	2021-04-29	Maria Soraya Carrancio ANTON	Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dion
AU2020369496B2 (en)	2019-10-21	2026-03-26	Celgene Corporation	Solid forms comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising the same and their use
CN114885603A (zh)	2019-10-21	2022-08-09	新基公司	使用2-(2,6-二氧代哌啶-3-基)-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异二氢吲哚-1,3-二酮治疗慢性淋巴细胞白血病的方法
CN110746400B (zh) *	2019-11-07	2021-12-17	郑州大学	一种靶向雄激素受体的荧光探针及其制备方法
US12103924B2 (en)	2020-06-01	2024-10-01	Icahn School Of Medicine At Mount Sinai	Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
CA3208313A1 (en)	2021-01-13	2022-07-21	Monte Rosa Therapeutics Ag	Isoindolinone compounds
CN115504963A (zh) *	2021-06-22	2022-12-23	苏州开拓药业股份有限公司	一种c-Myc蛋白降解剂
CA3240524A1 (en) *	2021-12-08	2023-06-15	Gluetacs Therapeutics (Shanghai) Co., Ltd.	E3 ubiquitin ligase ligand compound, protein degrader developed based thereon and their applications
JP2025523393A (ja)	2022-06-06	2025-07-23	シーフォーセラピューティクス，インコーポレイテッド	二環式置換グルタルイミドセレブロンバインダー

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5635517B1 (en) *	1996-07-24	1999-06-29	Celgene Corp	Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) *	1996-07-24	2001-08-28	Celgene Corporation	Isoindolines, method of use, and pharmaceutical compositions
ES2243052T3 (es) *	1998-03-16	2005-11-16	Celgene Corporation	Derivados de la 2- (2,6-dioxopiperidin-3-il) isoindolina, su preparacion y su empleo como inhibidores de las citocinas inflamatorias.
US7091353B2 (en)	2000-12-27	2006-08-15	Celgene Corporation	Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) *	2000-12-27	2003-03-06	Robarge Michael J.	Isoindole-imide compounds, compositions, and uses thereof
US7323479B2 (en)	2002-05-17	2008-01-29	Celgene Corporation	Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7968569B2 (en) *	2002-05-17	2011-06-28	Celgene Corporation	Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
WO2004054977A1 (en) *	2002-12-13	2004-07-01	Cytopia Pty Ltd	Nicotinamide-based kinase inhibitors
US20050143344A1 (en) *	2003-12-30	2005-06-30	Zeldis Jerome B.	Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
KR101299321B1 (ko) *	2005-06-30	2013-08-26	셀진 코포레이션	4-아미노-2-(2,6-디옥소피페리딘-3-일)이소인돌린-1,3-디온화합물의 제조 방법
DK2076260T3 (da) *	2006-09-15	2011-06-27	Celgene Corp	N-methylaminomethyl-isoindol-forbindelser og sammensætninger, der indeholder disse, samt fremgangsmåder til deres anvendelse

2007
- 2007-09-14 DK DK07838415.3T patent/DK2076260T3/da active
- 2007-09-14 WO PCT/US2007/020201 patent/WO2008033567A1/en not_active Ceased
- 2007-09-14 CA CA2663376A patent/CA2663376C/en active Active
- 2007-09-14 PL PL07838415T patent/PL2076260T3/pl unknown
- 2007-09-14 RS RS20110258A patent/RS51725B/sr unknown
- 2007-09-14 US US11/901,291 patent/US8648096B2/en active Active
- 2007-09-14 MX MX2009002666A patent/MX2009002666A/es active IP Right Grant
- 2007-09-14 UA UAA200903664A patent/UA95975C2/ru unknown
- 2007-09-14 NZ NZ575689A patent/NZ575689A/en not_active IP Right Cessation
- 2007-09-14 ZA ZA200901852A patent/ZA200901852B/xx unknown
- 2007-09-14 SI SI200730569T patent/SI2076260T1/sl unknown
- 2007-09-14 HR HR20110261T patent/HRP20110261T1/hr unknown
- 2007-09-14 CN CN2013102182141A patent/CN103382197A/zh active Pending
- 2007-09-14 TW TW096134612A patent/TW200819435A/zh unknown
- 2007-09-14 KR KR1020097006986A patent/KR20090050107A/ko not_active Withdrawn
- 2007-09-14 CL CL200702670A patent/CL2007002670A1/es unknown
- 2007-09-14 EP EP07838415A patent/EP2076260B1/en active Active
- 2007-09-14 DE DE602007013436T patent/DE602007013436D1/de active Active
- 2007-09-14 AT AT07838415T patent/ATE502634T1/de active
- 2007-09-14 ES ES07838415T patent/ES2361584T3/es active Active
- 2007-09-14 PT PT07838415T patent/PT2076260E/pt unknown
- 2007-09-14 JP JP2009528337A patent/JP5567339B2/ja active Active
- 2007-09-14 RU RU2009114159/15A patent/RU2009114159A/ru not_active Application Discontinuation
- 2007-09-14 CN CNA2007800424312A patent/CN101534820A/zh active Pending
- 2007-09-17 PE PE2007001253A patent/PE20080832A1/es not_active Application Discontinuation
- 2007-09-17 AR ARP070104112A patent/AR062875A1/es unknown
2009
- 2009-03-12 IL IL197566A patent/IL197566A0/en unknown
- 2009-03-13 NI NI200900031A patent/NI200900031A/es unknown
- 2009-03-30 CR CR10696A patent/CR10696A/es not_active Application Discontinuation
- 2009-04-03 CO CO09034806A patent/CO6180446A2/es not_active Application Discontinuation
2011
- 2011-05-20 CY CY20111100500T patent/CY1112558T1/el unknown
2013
- 2013-12-30 US US14/144,292 patent/US20140113935A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20140113935A1 (en)	2014-04-24
US20080214615A1 (en)	2008-09-04
EP2076260B1 (en)	2011-03-23
JP2010503688A (ja)	2010-02-04
AR062875A1 (es)	2008-12-10
SI2076260T1 (sl)	2011-05-31
TW200819435A (en)	2008-05-01
CA2663376C (en)	2015-01-06
ZA200901852B (en)	2010-06-30
ATE502634T1 (de)	2011-04-15
PT2076260E (pt)	2011-06-07
ES2361584T3 (es)	2011-06-20
CL2007002670A1 (es)	2008-05-16
RU2009114159A (ru)	2010-10-20
CA2663376A1 (en)	2008-03-20
CR10696A (es)	2009-05-13
CO6180446A2 (es)	2010-07-19
UA95975C2 (ru)	2011-09-26
WO2008033567A1 (en)	2008-03-20
RS51725B (sr)	2011-10-31
CY1112558T1 (el)	2016-02-10
DK2076260T3 (da)	2011-06-27
KR20090050107A (ko)	2009-05-19
HRP20110261T1 (hr)	2011-05-31
CN101534820A (zh)	2009-09-16
NZ575689A (en)	2011-12-22
CN103382197A (zh)	2013-11-06
IL197566A0 (en)	2009-12-24
PE20080832A1 (es)	2008-08-06
US8648096B2 (en)	2014-02-11
DE602007013436D1 (de)	2011-05-05
NI200900031A (es)	2010-02-01
MX2009002666A (es)	2009-04-09
EP2076260A1 (en)	2009-07-08
JP5567339B2 (ja)	2014-08-06

Publication	Publication Date	Title
IL197566A0 (en)	2009-12-24	N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
IL189795A0 (en)	2008-08-07	Isoindole-imide compounds and compositions comprising and methods of using the same
PT2101766T (pt)	2016-12-28	Composições e métodos de utilização de (r)-pramipexole
PL2335782T3 (pl)	2021-01-11	Zastosowanie kompozycji zawierającej HFCO-1233zd
PL1940839T3 (pl)	2013-12-31	Pirydopirymidynonowe inhibitory PI3Kalfa
IL181543A0 (en)	2007-07-04	Dendrimer based compositions and methods of using the same
GB0718972D0 (en)	2007-11-07	Compounds and methods of making the compounds
ZA200808431B (en)	2009-09-30	Fungicidal compositions and methods of using the same
IL191072A0 (en)	2008-12-29	Therapeutic compositions and methods
IL180907A0 (en)	2007-07-04	Risedronate compositions and their methods of use
ZA200900388B (en)	2010-03-31	Compositions and methods for the treatment of mucositis
IL197804A0 (en)	2009-12-24	Compositions for the trearment of hepatitis c and methods for using compositions for the treatment of hepatitis c
PL2101766T3 (pl)	2017-04-28	Kompozycje i sposoby stosowania (R)-pramipeksolu
PL2069467T3 (pl)	2015-02-27	Kompozycje wydzielające i sposoby stosowania
EP2104554A4 (en)	2010-12-22	particle compositions
AU2007291030A8 (en)	2009-04-09	Novel compositions and methods
IL186606A0 (en)	2008-01-20	Compositions and uses of amooranin compounds
GB0412584D0 (en)	2004-07-07	Composition of matter
IL180195A0 (en)	2007-06-03	Aequorin-containing compositions and methods of using same
EP2046109A4 (en)	2010-01-06	PHOTOSYNTHETIC ORGANISMS, COMPOSITIONS AND METHODS FOR GENERATING THESE ORGANISMS
GB0501348D0 (en)	2005-03-02	Compositions and methods
IL195845A0 (en)	2011-08-01	Methods of making and using rubidium-81-containing compositions
IL192614A0 (en)	2009-02-11	Antiseptic compositions and methods of using same
ZA200806668B (en)	2009-10-28	Antiseptic compositions and methods of using same
GB0607565D0 (en)	2006-05-24	Methods and compositions